Jane Henderson - Jun 16, 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Director
Signature
/s/ Jonathan Young, Attorney-in-Fact
Stock symbol
AKRO
Transactions as of
Jun 16, 2023
Transactions value $
-$1,886,285
Form type
4
Date filed
6/21/2023, 05:47 PM
Previous filing
May 19, 2023
Next filing
Jun 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $280K +40K $7.01* 40K Jun 16, 2023 Direct
transaction AKRO Common Stock Sale -$941K -17.5K -43.76% $53.79 22.5K Jun 16, 2023 Direct F1
transaction AKRO Common Stock Sale -$1.23M -22.5K -100% $54.46 0 Jun 16, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -40K -73% $0.00 14.8K Jun 16, 2023 Common Stock 40K $7.01 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $53.20 to $54.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $54.20 to $55.135, inclusive.
F3 The options are vested and currently exercisable.